Home LiteratureArticle Details
PMID: 16014946 Published · ppublish English Comparative Study Journal Article Research Support, Non-U.S. Gov't

Characterization of immune responses induced by intramuscular vaccination with DNA vaccines encoding measles virus hemagglutinin and/or fusion proteins.

Journal of virology ·Vol. 79 ·No. 15 ·2005-08-00 ·Pages 9854-61

Song MK, Vindurampulle CJ, Capozzo AV, Ulmer J, Polo JM, Pasetti MF, Barry EM, Levine MM

Abstract

Measles virus (MV) hemagglutinin (MV-H) and fusion (MV-F) proteins induce plaque reduction neutralizing (PRN) antibodies and cell-mediated immune responses that protect against clinical measles. DNA vaccines that encode MV-H and MV-F are being investigated as a new generation of measles vaccine to protect infants too young to receive currently licensed attenuated measles vaccines. However, it is unclear whether DNA vaccines encoding both MV-H and MV-F act synergistically to induce stronger immunity than immunization with plasmids encoding MV-H or MV-F alone. To address this question, we generated Sindbis virus-based pSINCP DNA vaccines that encode either MV-H or MV-F alone or bicistronic or fusion system vectors that encode both MV-H and MV-F (to mimic MV infection where both MV-H and MV-F proteins are expressed by the same mammalian cell). Mice immunized with DNA vaccine encoding MV-H alone developed significantly greater PRN titers than mice immunized with bicistronic constructs. Interestingly, the presence of MV-F in the bicistronic constructs stimulated serum MV-specific immunoglobulin G of reduced avidity. By contrast, mice immunized with bicistronic constructs induced equivalent or higher levels of MV-specific gamma interferon responses than mice immunized with DNA vaccine encoding MV-H alone. These data will help guide the design of DNA-based MV vaccines to be used early in life in a heterologous prime-boost strategy.

MeSH Terms
Animals Antibodies, Viral/blood,immunology Antibody Affinity Drug Evaluation, Preclinical Female Hemagglutinins, Viral/immunology Immunoglobulin G/blood,immunology Injections, Intramuscular Interferon-gamma/biosynthesis Measles/immunology Measles Vaccine/administration & dosage,immunology Measles virus/immunology Mice Mice, Inbred BALB C Vaccination Vaccines, DNA/immunology Viral Fusion Proteins/immunology
Chemicals
Antibodies, Viral Hemagglutinins, Viral Immunoglobulin G Measles Vaccine Vaccines, DNA Viral Fusion Proteins Interferon-gamma
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Song Man Ki
Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, 21201, USA.
Vindurampulle Christofer J
Capozzo Alejandra V E
Ulmer Jeffrey
Polo John M
Pasetti Marcela F
Barry Eileen M
Levine Myron M
References (53)
53 references, click to expand
  1. Measles epidemic in Harare, Zimbabwe, despite high measles immunization coverage rates.
    Bull World Health Organ. 1991;69(2):213-9 PMID: 1860149
  2. Measles antibody: reevaluation of protective titers.
    J Infect Dis. 1990 Nov;162(5):1036-42 PMID: 2230231
  3. The 1st International Standard for anti-measles serum.
    Biologicals. 1991 Jul;19(3):237-41 PMID: 1954005
  4. Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus.
    J Virol. 1993 Oct;67(10):6025-32 PMID: 8371352
  5. Characterization of a cleavage mutant of the measles virus fusion protein defective in syncytium formation.
    J Virol. 1994 Oct;68(10):6770-4 PMID: 8084012
  6. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program.
    N Engl J Med. 1994 Nov 24;331(21):1397-402 PMID: 7969278
  7. Measles elimination in the Americas. Evolving strategies.
    JAMA. 1996 Jan 17;275(3):224-9 PMID: 8604176
  8. Immune-mediated destruction of transfected muscle fibers after direct gene transfer with antigen-expressing plasmid DNA.
    Gene Ther. 1997 Mar;4(3):181-8 PMID: 9135731
  9. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study.
    Lancet. 1997 May 17;349(9063):1436-42 PMID: 9164317
  10. Enzyme-linked immunosorbent assay-IgG antibody avidity test for single sample serologic evaluation of measles vaccines.
    J Med Virol. 1997 Jul;52(3):275-9 PMID: 9210036
  11. Early studies on DNA-based immunizations for measles virus.
    Vaccine. 1997 Jun;15(8):888-91 PMID: 9234540
  12. DNA immunization circumvents deficient induction of T helper type 1 and cytotoxic T lymphocyte responses in neonates and during early life.
    Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8726-31 PMID: 9238045
  13. Optimal induction of hepatitis C virus envelope-specific immunity by bicistronic plasmid DNA inoculation with the granulocyte-macrophage colony-stimulating factor gene.
    J Virol. 1998 Oct;72(10):8430-6 PMID: 9733898
  14. Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin- and neuraminidase-expressing DNAs.
    Vaccine. 1999 Feb 26;17(7-8):653-9 PMID: 10067670
  15. Production of atypical measles in rhesus macaques: evidence for disease mediated by immune complex formation and eosinophils in the presence of fusion-inhibiting antibody.
    Nat Med. 1999 Jun;5(6):629-34 PMID: 10371500
  16. Proteolytic cleavage of the fusion protein but not membrane fusion is required for measles virus-induced immunosuppression in vitro.
    J Virol. 2000 Feb;74(4):1985-93 PMID: 10644371
  17. Recombinant measles virus requiring an exogenous protease for activation of infectivity.
    J Gen Virol. 2000 Feb;81(Pt 2):441-9 PMID: 10644843
  18. Secondary measles vaccine failures identified by measurement of IgG avidity: high occurrence among teenagers vaccinated at a young age.
    Epidemiol Infect. 2000 Apr;124(2):263-71 PMID: 10813152
  19. Successful DNA immunization against measles: neutralizing antibody against either the hemagglutinin or fusion glycoprotein protects rhesus macaques without evidence of atypical measles.
    Nat Med. 2000 Jul;6(7):776-81 PMID: 10888926
  20. Measles virus-induced immunosuppression in vitro is independent of complex glycosylation of viral glycoproteins and of hemifusion.
    J Virol. 2000 Aug;74(16):7548-53 PMID: 10906208
  21. Identification of effective constituents of influenza vaccine by immunization with plasmid DNAs encoding viral proteins.
    Jpn J Infect Dis. 2000 Dec;53(6):219-28 PMID: 11227019
  22. Immune-mediated destruction of transfected myocytes following DNA vaccination occurs via multiple mechanisms.
    Gene Ther. 2001 Sep;8(18):1395-400 PMID: 11571579
  23. Altered synthesis of interleukin-12 and type 1 and type 2 cytokinesin rhesus macaques during measles and atypical measles.
    J Infect Dis. 2002 Jan 1;185(1):13-9 PMID: 11756976
  24. Analysis of receptor (CD46, CD150) usage by measles virus.
    J Gen Virol. 2002 Jun;83(Pt 6):1431-6 PMID: 12029158
  25. New tendencies and strategies in international immunisation: GAVI and The Vaccine Fund.
    Vaccine. 2003 Jan 30;21(7-8):587-92 PMID: 12531322
  26. Measles virus infects and suppresses proliferation of T lymphocytes from transgenic mice bearing human signaling lymphocytic activation molecule.
    J Virol. 2003 Mar;77(6):3505-15 PMID: 12610126
  27. DNA vaccination of infants in the presence of maternal antibody: a measles model in the primate.
    Virology. 2003 Mar 1;307(1):67-75 PMID: 12667815
  28. Attenuated Salmonella enterica serovar Typhi and Shigella flexneri 2a strains mucosally deliver DNA vaccines encoding measles virus hemagglutinin, inducing specific immune responses and protection in cotton rats.
    J Virol. 2003 May;77(9):5209-17 PMID: 12692223
  29. Impact of alternative approaches to accelerated measles control: experience in the African region, 1996-2002.
    J Infect Dis. 2003 May 15;187 Suppl 1:S36-43 PMID: 12721884
  30. The global burden of measles in the year 2000--a model that uses country-specific indicators.
    J Infect Dis. 2003 May 15;187 Suppl 1:S8-14 PMID: 12721886
  31. Failure of targeted urban supplemental measles vaccination campaigns (1997-1999) to prevent measles epidemics in Mozambique (1998-2001).
    J Infect Dis. 2003 May 15;187 Suppl 1:S51-7 PMID: 12721891
  32. Evaluation of urban measles mass campaigns for children aged 9-59 months in Mali.
    J Infect Dis. 2003 May 15;187 Suppl 1:S69-73 PMID: 12721894
  33. Measles incidence before and after mass vaccination campaigns in Burkina Faso.
    J Infect Dis. 2003 May 15;187 Suppl 1:S80-5 PMID: 12721896
  34. Differential effects of priming with DNA vaccines encoding the hemagglutinin and/or fusion proteins on cytokine responses after measles virus challenge.
    J Infect Dis. 2003 Jun 1;187(11):1794-800 PMID: 12751038
  35. A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles.
    Nat Med. 2003 Sep;9(9):1209-13 PMID: 12925847
  36. Epidemiology of measles in the Central Region of Ghana: a five-year case review in three district hospitals.
    East Afr Med J. 2003 Jun;80(6):312-7 PMID: 12953741
  37. Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines.
    J Virol. 2003 Dec;77(23):12764-72 PMID: 14610198
  38. Measles virus protein-specific IgM, IgA, and IgG subclass responses during the acute and convalescent phase of infection.
    J Med Virol. 2004 Feb;72(2):290-8 PMID: 14695672
  39. Identification of primary and secondary measles vaccine failures by measurement of immunoglobulin G avidity in measles cases during the 1997 São Paulo epidemic.
    Clin Diagn Lab Immunol. 2004 Jan;11(1):119-22 PMID: 14715557
  40. Measles mortality reduction--West Africa, 1996-2002.
    MMWR Morb Mortal Wkly Rep. 2004 Jan 23;53(2):28-30 PMID: 14737060
  41. Prior DNA vaccination does not interfere with the live-attenuated measles vaccine.
    Vaccine. 2004 Jan 26;22(5-6):762-5 PMID: 14741170
  42. Protection against challenge with measles virus (MV) in infant macaques by an MV DNA vaccine administered in the presence of neutralizing antibody.
    J Infect Dis. 2004 Jun 1;189(11):2064-71 PMID: 15143474
  43. Enhanced efficacy of DNA vaccination against Her-2/neu tumor antigen by genetic adjuvants.
    Int J Cancer. 2004 Aug 10;111(1):86-95 PMID: 15185348
  44. Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines.
    JAMA. 1967 Dec 18;202(12):1075-80 PMID: 6072745
  45. Atypical measles. Severe illness in recipients of killed measles virus vaccine upon exposure to natural infection.
    JAMA. 1972 Dec 11;222(11):1415-6 PMID: 4678322
  46. Differences in the appearance of antibodies to structural components of measles virus after immunization with inactivated and live virus.
    J Infect Dis. 1975 Sep;132(3):262-9 PMID: 1159329
  47. Synergistic protective effect in rabbits of immunization with Vibrio cholerae lipopolysaccharide and toxin/toxoid.
    Infect Immun. 1976 Mar;13(3):735-40 PMID: 1270131
  48. Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure.
    J Pediatr. 1977 Nov;91(5):715-8 PMID: 909009
  49. Importance of antibodies to the fusion glycoprotein of paramyxoviruses in the prevention of spread of infection.
    J Exp Med. 1980 Feb 1;151(2):275-88 PMID: 6766174
  50. Age-specific occurrence rates of measles in urban, peri-urban, and rural environments: implications for time of vaccination.
    Lancet. 1983 Aug 6;2(8345):324-6 PMID: 6135839
  51. Measles control efforts in urban Africa complicated by high incidence of measles in the first year of life.
    Am J Epidemiol. 1988 Apr;127(4):788-94 PMID: 3354544
  52. Placebo-controlled trial of two acellular pertussis vaccines in Sweden--protective efficacy and adverse events. Ad Hoc Group for the Study of Pertussis Vaccines.
    Lancet. 1988 Apr 30;1(8592):955-60 PMID: 2896826
  53. The burden of acute respiratory infection due to measles in developing countries and the potential impact of measles vaccine.
    Rev Infect Dis. 1991 May-Jun;13 Suppl 6:S555-61 PMID: 1862285
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
2005-08-00
Pages
9854-61
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC1181616
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com